Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.

Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use. Lancet Neurol (2009) 2.98

Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci (2009) 2.95

Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol (2012) 2.24

Regulation of inflammation by short chain fatty acids. Nutrients (2011) 2.15

Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res (2010) 2.01

Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov (2009) 2.00

Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J (2008) 1.76

Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology (2011) 1.66

Epigenetics in the nervous system. J Neurosci (2008) 1.65

Reactive astrocytes as therapeutic targets for CNS disorders. Neurotherapeutics (2010) 1.60

Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci (2008) 1.58

Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab (2010) 1.53

The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem (2009) 1.53

Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev (2013) 1.52

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol (2009) 1.45

Hydroxamate-based histone deacetylase inhibitors can protect neurons from oxidative stress via a histone deacetylase-independent catalase-like mechanism. Chem Biol (2015) 1.42

Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med (2011) 1.41

HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res (2008) 1.36

HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension (2010) 1.35

Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dis (2009) 1.29

Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem (2009) 1.28

Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J (2009) 1.23

Histone modifications, DNA methylation, and schizophrenia. Neurosci Biobehav Rev (2009) 1.17

Neuroinflammation in Huntington's disease. J Neural Transm (Vienna) (2010) 1.16

HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol Res (2010) 1.15

Effects of alcohol on histone deacetylase 2 (HDAC2) and the neuroprotective role of trichostatin A (TSA). Alcohol Clin Exp Res (2011) 1.11

Trade-off between cancer and aging: what role do other diseases play? Evidence from experimental and human population studies. Mech Ageing Dev (2008) 1.10

Valproic acid increases white matter repair and neurogenesis after stroke. Neuroscience (2012) 1.09

Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes. J Neuroimmune Pharmacol (2010) 1.08

Aminoglycoside-induced histone deacetylation and hair cell death in the mouse cochlea. J Neurochem (2009) 1.07

The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms. Neuropsychopharmacology (2010) 1.07

Effect of valproic acid on acute lung injury in a rodent model of intestinal ischemia reperfusion. Resuscitation (2011) 1.07

Depression research: where are we now? Mol Brain (2010) 1.06

ATF3-mediated epigenetic regulation protects against acute kidney injury. J Am Soc Nephrol (2010) 1.01

Ischemic preconditioning alters the epigenetic profile of the brain from ischemic intolerance to ischemic tolerance. Neurotherapeutics (2013) 1.01

Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells. BMC Neurosci (2011) 1.00

Post-insult valproic acid-regulated microRNAs: potential targets for cerebral ischemia. Am J Transl Res (2012) 0.99

Lithium ameliorates neurodegeneration, suppresses neuroinflammation, and improves behavioral performance in a mouse model of traumatic brain injury. J Neurotrauma (2011) 0.99

Histone deacetylase inhibitors sodium butyrate and valproic acid delay spontaneous cell death in purified rat retinal ganglion cells. Mol Vis (2011) 0.98

Trade-offs between cancer and other diseases: do they exist and influence longevity? Rejuvenation Res (2010) 0.98

Activated microglia decrease histone acetylation and Nrf2-inducible anti-oxidant defence in astrocytes: restoring effects of inhibitors of HDACs, p38 MAPK and GSK3β. Neurobiol Dis (2011) 0.98

Pharmacological induction of neuroglobin expression. Pharmacology (2011) 0.97

Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience (2011) 0.97

Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies. J Neurochem (2010) 0.97

From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology. Am J Physiol Cell Physiol (2014) 0.96

Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Res (2010) 0.96

HDAC inhibitors mitigate ischemia-induced oligodendrocyte damage: potential roles of oligodendrogenesis, VEGF, and anti-inflammation. Am J Transl Res (2014) 0.95

The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin Neurosci (2009) 0.95

Role of histone acetylation in the activity-dependent regulation of sulfiredoxin and sestrin 2. Epigenetics (2009) 0.95

A transient ischemic environment induces reversible compaction of chromatin. Genome Biol (2015) 0.94

Targeting histone deacetylases for the treatment of disease. J Cell Mol Med (2008) 0.94

Environmental enrichment induces behavioral recovery and enhanced hippocampal cell proliferation in an antidepressant-resistant animal model for PTSD. PLoS One (2010) 0.94

Epigenetic mechanisms in cerebral ischemia. J Cereb Blood Flow Metab (2013) 0.93

Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. Acta Pharmacol Sin (2011) 0.93

Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries. Mol Med (2011) 0.93

Targeting microglial activation in stroke therapy: pharmacological tools and gender effects. Curr Med Chem (2014) 0.93

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Med J (2016) 0.93

Neuroprotection by the histone deacetylase inhibitor trichostatin A in a model of lipopolysaccharide-sensitised neonatal hypoxic-ischaemic brain injury. J Neuroinflammation (2012) 0.92

HDAC4/5-HMGB1 signalling mediated by NADPH oxidase activity contributes to cerebral ischaemia/reperfusion injury. J Cell Mol Med (2013) 0.92

Histone deacetylase inhibition alters histone methylation associated with heat shock protein 70 promoter modifications in astrocytes and neurons. Neuropharmacology (2010) 0.92

Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health? Neurosci Lett (2016) 0.91

Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats. Psychopharmacology (Berl) (2011) 0.90

The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis. Mol Med (2011) 0.90

Pharmacology of epigenetics in brain disorders. Br J Pharmacol (2009) 0.90

Valproic acid protects motor neuron death by inhibiting oxidative stress and endoplasmic reticulum stress-mediated cytochrome C release after spinal cord injury. J Neurotrauma (2014) 0.90

Sodium butyrate protects against severe burn-induced remote acute lung injury in rats. PLoS One (2013) 0.90

Epigenetic impact of curcumin on stroke prevention. Metab Brain Dis (2014) 0.89

Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain. Am J Nucl Med Mol Imaging (2013) 0.88

Role of salt-induced kinase 1 in androgen neuroprotection against cerebral ischemia. J Cereb Blood Flow Metab (2010) 0.88

Novel protective effects of histone deacetylase inhibition on stroke and white matter ischemic injury. Neurotherapeutics (2013) 0.88

Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury. Proc Natl Acad Sci U S A (2013) 0.87

HDAC inhibitors in kidney development and disease. Pediatr Nephrol (2012) 0.86

Molecular targets for tumor radiosensitization. Chem Rev (2009) 0.86

Neurological disorders and therapeutics targeted to surmount the blood-brain barrier. Int J Nanomedicine (2012) 0.86

Effects of valproic acid and dexamethasone administration on early bio-markers and gene expression profile in acute kidney ischemia-reperfusion injury in the rat. PLoS One (2015) 0.85

Acetylation: a lysine modification with neuroprotective effects in ischemic retinal degeneration. Exp Eye Res (2014) 0.85

The neuroprotective effect of post ischemic brief mild hypothermic treatment correlates with apoptosis, but not with gliosis in endothelin-1 treated rats. BMC Neurosci (2012) 0.85

Effects of valproic acid, a histone deacetylase inhibitor, on improvement of locomotor function in rat spinal cord injury based on epigenetic science. Iran Biomed J (2012) 0.84

LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice. Biol Blood Marrow Transplant (2012) 0.83

Histone deacetylase expression in white matter oligodendrocytes after stroke. Neurochem Int (2014) 0.83

Epigenetics and the modulation of neuroinflammation. Neurotherapeutics (2013) 0.83

Epigenetic mechanisms of neuroplasticity and the implications for stroke recovery. Exp Neurol (2014) 0.83

Butyrate protects rat liver against total hepatic ischemia reperfusion injury with bowel congestion. PLoS One (2014) 0.83

Potential non-oncological applications of histone deacetylase inhibitors. Am J Transl Res (2011) 0.82

T33, a novel peroxisome proliferator-activated receptor γ/α agonist, exerts neuroprotective action via its anti-inflammatory activities. Acta Pharmacol Sin (2011) 0.82

Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned? Int J Biol Sci (2014) 0.82

Inhibition of CD200R1 expression by C/EBP β in reactive microglial cells. J Neuroinflammation (2012) 0.82

Acetate supplementation reduces microglia activation and brain interleukin-1β levels in a rat model of Lyme neuroborreliosis. J Neuroinflammation (2012) 0.81

Role of GABAergic activity of sodium valproate against ischemia-reperfusion-induced acute kidney injury in rats. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.81

Anti-inflammatory effect of sodium butyrate preconditioning during myocardial ischemia/reperfusion. Exp Ther Med (2014) 0.81

Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson's Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties. J Neurodegener Dis (2015) 0.81

General Anesthesia Causes Epigenetic Histone Modulation of c-Fos and Brain-derived Neurotrophic Factor, Target Genes Important for Neuronal Development in the Immature Rat Hippocampus. Anesthesiology (2016) 0.80

MicroRNAs: new biomarkers and therapeutic targets after cardiac arrest? Crit Care (2015) 0.80

Protective Effects of Valproic Acid, a Histone Deacetylase Inhibitor, against Hyperoxic Lung Injury in a Neonatal Rat Model. PLoS One (2015) 0.80

Histone Deacetylase Inhibitor Trichostatin A Ameliorated Endotoxin-Induced Neuroinflammation and Cognitive Dysfunction. Mediators Inflamm (2015) 0.80

Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors. Br J Pharmacol (2015) 0.80

The Role of the Microbial Metabolites Including Tryptophan Catabolites and Short Chain Fatty Acids in the Pathophysiology of Immune-Inflammatory and Neuroimmune Disease. Mol Neurobiol (2016) 0.80

The Smn-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy. PLoS One (2014) 0.79

Valproate ameliorates nitroglycerin-induced migraine in trigeminal nucleus caudalis in rats through inhibition of NF-кB. J Headache Pain (2016) 0.79

Class I to III histone deacetylases differentially regulate inflammation-induced matrix metalloproteinase 9 expression in primary amnion cells. Reprod Sci (2014) 0.79

Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci (2007) 11.24

Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia (2007) 5.67

Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol (2005) 4.96

Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J (2005) 3.60

Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther (2003) 3.29

Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem (2002) 3.14

NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem (2003) 2.92

Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol (2008) 2.46

Increased systemic and brain cytokine production and neuroinflammation by endotoxin following ethanol treatment. J Neuroinflammation (2008) 2.25

Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem (2004) 2.21

Peer support among adults with serious mental illness: a report from the field. Schizophr Bull (2006) 2.19

Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci (2002) 1.87

Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J (2003) 1.81

Role of nitric oxide in inflammation-mediated neurodegeneration. Ann N Y Acad Sci (2002) 1.75

Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci (2003) 1.73

In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord (2002) 1.68

Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology (2011) 1.66

Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J Neural Transm (Vienna) (2010) 1.66

Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci U S A (2003) 1.62

Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci (2006) 1.61

FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron (2008) 1.59

Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci (2003) 1.58

Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem (2002) 1.58

Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci (2008) 1.58

Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. J Biol Chem (2006) 1.57

PET imaging with [11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat. Neurosci Lett (2006) 1.56

Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem (2002) 1.55

Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab (2010) 1.53

The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem (2009) 1.53

Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev (2013) 1.52

Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry (2010) 1.51

Craniotomy: true sham for traumatic brain injury, or a sham of a sham? J Neurotrauma (2011) 1.49

Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J Biol Chem (2006) 1.48

Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect (2003) 1.47

Cinnamon extract (traditional herb) potentiates in vivo insulin-regulated glucose utilization via enhancing insulin signaling in rats. Diabetes Res Clin Pract (2003) 1.46

Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med (2004) 1.44

Enhanced presynaptic neurotransmitter release in the anterior cingulate cortex of mice with chronic pain. J Neurosci (2006) 1.43

Mental illness, criminality, and citizenship revisited. J Am Acad Psychiatry Law (2012) 1.42

Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord (2002) 1.41

Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J (2004) 1.40

Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther (2010) 1.39

Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood-brain barrier. FASEB J (2008) 1.39

Astrogliosis in CNS pathologies: is there a role for microglia? Mol Neurobiol (2010) 1.38

Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol (2008) 1.38

HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci (2011) 1.38

Violent victimization of persons with co-occurring psychiatric and substance use disorders. Psychiatr Serv (2003) 1.37

GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev (2007) 1.36

Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res (2009) 1.35

Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology (2002) 1.34

The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxid Redox Signal (2005) 1.34

Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int J Neuropsychopharmacol (2010) 1.31

Interactive role of the toll-like receptor 4 and reactive oxygen species in LPS-induced microglia activation. Glia (2005) 1.31

Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect (2011) 1.30

Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther (2003) 1.30

Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem (2009) 1.28

The treatment relationship in peer-based and regular case management for clients with severe mental illness. Psychiatr Serv (2006) 1.28

Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase. J Neuroinflammation (2007) 1.27

Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia (2007) 1.26

Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase. J Pharmacol Exp Ther (2006) 1.25

Role of reactive oxygen species in LPS-induced production of prostaglandin E2 in microglia. J Neurochem (2004) 1.24

Gosha-jinki-gan (a Herbal Complex) Corrects Abnormal Insulin Signaling. Evid Based Complement Alternat Med (2004) 1.24

Traumatic brain injury-induced expression and phosphorylation of pyruvate dehydrogenase: a mechanism of dysregulated glucose metabolism. Neurosci Lett (2009) 1.23

Increased anxiety-like behavior and enhanced synaptic efficacy in the amygdala of GluR5 knockout mice. PLoS One (2007) 1.22

A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J (2006) 1.22

Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology (2010) 1.21

Validation of a multimarker model for assessing risk of type 2 diabetes from a five-year prospective study of 6784 Danish people (Inter99). J Diabetes Sci Technol (2009) 1.20

Role of oxidative stress in epileptic seizures. Neurochem Int (2011) 1.20

The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci (2008) 1.19

Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res Mol Brain Res (2004) 1.18

Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett (2003) 1.18

Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol (2008) 1.18

Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci (2002) 1.16

Pro-inflammatory cytokines and lipopolysaccharide induce changes in cell morphology, and upregulation of ERK1/2, iNOS and sPLA₂-IIA expression in astrocytes and microglia. J Neuroinflammation (2011) 1.16

NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Glia (2013) 1.16

Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. FASEB J (2005) 1.15

Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Prog Neurobiol (2011) 1.14

Potent anti-inflammatory and neuroprotective effects of TGF-beta1 are mediated through the inhibition of ERK and p47phox-Ser345 phosphorylation and translocation in microglia. J Immunol (2008) 1.13

Microglia-mediated neurotoxicity is inhibited by morphine through an opioid receptor-independent reduction of NADPH oxidase activity. J Immunol (2007) 1.13

MAC1 mediates LPS-induced production of superoxide by microglia: the role of pattern recognition receptors in dopaminergic neurotoxicity. Glia (2007) 1.11

Systematic review on the compatibility of Shuanghuanglian injection combined with western medical injections. J Evid Based Med (2010) 1.11

Reactive microgliosis: extracellular micro-calpain and microglia-mediated dopaminergic neurotoxicity. Brain (2010) 1.10

Study of hepatotoxicity of naltrexone in the treatment of alcoholism. Alcohol (2006) 1.09

NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends Pharmacol Sci (2012) 1.08

The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms. Neuropsychopharmacology (2010) 1.07

Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology (2009) 1.07

Inhibition by naloxone stereoisomers of beta-amyloid peptide (1-42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. J Pharmacol Exp Ther (2002) 1.07

Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J (2003) 1.07

Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry (2010) 1.06

Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model. Stroke (2011) 1.06

Inhibition of IkappaB kinase-beta protects dopamine neurons against lipopolysaccharide-induced neurotoxicity. J Pharmacol Exp Ther (2010) 1.03

Endotoxin induces a delayed loss of TH-IR neurons in substantia nigra and motor behavioral deficits. Neurotoxicology (2008) 1.03

Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells. Immunology (2008) 1.03

Beyond generic support: incidence and impact of invalidation in peer services for clients with severe mental illness. Psychiatr Serv (2008) 1.03